How to measure biomechanical properties today

Article

The primary function of biomechanical measurements is to improve safety and doctors can readily use these metrics in clinical practice today through the use of proxies, said William J. Dupps, MD.

The primary function of biomechanical measurements is to improve safety and doctors can readily use these metrics in clinical practice today through the use of proxies, said William J. Dupps, MD.

"Readily-measured variables that share some relationship to a biomechanical property of interest include central corneal thickness (CCT), corneal topography, or 'warpability', residual stromal thickness (RST) and time, which is useful to measure warpage recovery time," said Dr Dupps of the Cole Eye Institute, Cleveland, USA.

The advantage of proxies is that they can provide a rational, predictive variable for the safety of a given procedure, they are accessible and usually routine and population norms are well established.

He did, however, caution that there are problems using proxies. They are incomplete representations, they can be confounded by other uncontrollable or unmeasured variables and they can be insensitive to early disease.

Dr Dupps also reviewed the Ocular Response Analyser (ORA), which provides corneal hysteresis (CH) and corneal resistance factor (CRF) metrics, which provide keratoconic signals.

"While we are currently only using the corneal hysteresis value, clearly there is additional valuable information present in the shape of the measurement signal," he said.

Dr Dupps concluded by outlining tomorrow's challenges, among which are the need for a quantitative analysis of ORA signal morphology and to establish a conservative reference population as well as a "safe range" of CH, CRF and emergent variables.

Dr Dupps advised that the November issue of the Journal of Cataract and Refractive Surgery will report on advances in anatomic measurement.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.